Prelude Therapeutics INC (PRLD) — SEC Filings

Overview

Prelude Therapeutics INC (PRLD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 20, 2026: On April 20, 2026, Prelude Therapeutics Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements/Exhibits. The filing includes various exhibits, such as an iXBRL 8-K and numerous graphic files, likely related to presentations or data visualizat

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Prelude Therapeutics INC is neutral.

Filing Type Overview

Prelude Therapeutics INC (PRLD) has filed 16 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 8-K/A, 4 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (31)

• Prelude Therapeutics Files 8-K with Exhibits — 8-K · Apr 20, 2026 Risk: low
  On April 20, 2026, Prelude Therapeutics Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements/Exhibit
• 8-K Filing — 8-K · Apr 15, 2026
• Prelude Narrows Losses, Boosts Revenue Amid Strategic R&D Shift — 10-Q · Nov 12, 2025 Risk: high
  Prelude Therapeutics Inc. reported a net loss of $19.725 million for the three months ended September 30, 2025, a significant improvement from the $32.271 milli
• 8-K Filing — 8-K · Nov 4, 2025
• Prelude Therapeutics Announces CMO Departure, Appoints Interim — 8-K · Oct 17, 2025 Risk: medium
  On October 15, 2025, Prelude Therapeutics Incorporated announced the departure of Dr. Christopher V. Fountas as Chief Medical Officer. The company also announce
• Prelude Therapeutics Files 8-K — 8-K · Sep 19, 2025 Risk: low
  On September 18, 2025, Prelude Therapeutics Incorporated announced an "Other Event" in a Form 8-K filing. The specific nature of this event is not detailed in t
• Prelude Therapeutics' Cash Dwindles Amidst Mounting Losses — 10-Q · Aug 14, 2025 Risk: high
  Prelude Therapeutics Inc. reported a net loss of $31.2 million for the three months ended June 30, 2025, an improvement from a net loss of $34.7 million in the
• Prelude Therapeutics Appoints New Director — 8-K · Jun 13, 2025 Risk: low
  On June 11, 2025, Prelude Therapeutics Incorporated announced the election of Dr. Jonathan G. Drachman to its Board of Directors. Dr. Drachman, who has extensiv
• Prelude Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
  Prelude Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first qu
• Prelude Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
  Prelude Therapeutics Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting on June 12, 2025. The company, incorporated in Delaware
• Prelude Therapeutics Files 8-K Report — 8-K · Apr 25, 2025 Risk: low
  On April 25, 2025, Prelude Therapeutics Incorporated filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorpo
• Prelude Therapeutics Faces Nasdaq Delisting Notice — 8-K · Mar 28, 2025 Risk: high
  Prelude Therapeutics Incorporated announced on March 27, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued lis
• Prelude Therapeutics Files 2024 Annual Report — 10-K · Mar 10, 2025 Risk: medium
  Prelude Therapeutics Inc. filed its 10-K for the fiscal year ending December 31, 2024, on March 10, 2025. The company, operating in the Pharmaceutical Preparati
• Prelude Therapeutics Files 8-K: Officer/Director Changes & Financials — 8-K · Feb 5, 2025 Risk: medium
  On February 3, 2025, Prelude Therapeutics Incorporated filed an 8-K report detailing the departure of certain officers and directors, the election of new direct
• Prelude Therapeutics Files 8-K — 8-K · Dec 11, 2024 Risk: low
  On December 11, 2024, Prelude Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corpora
• Prelude Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
  Prelude Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and business operations. Key
• 8-K Filing — 8-K · Oct 24, 2024
• Prelude Therapeutics Files 8-K Report — 8-K · Sep 13, 2024 Risk: low
  On September 13, 2024, Prelude Therapeutics Incorporated filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibit
• Prelude Therapeutics Files 8-K Report — 8-K · Sep 9, 2024 Risk: low
  On September 9, 2024, Prelude Therapeutics Incorporated filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and
• Prelude Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: low
  Prelude Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company's financial statements and disclosures are presented, including detail
• Prelude Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 18, 2024 Risk: low
  On June 14, 2024, Prelude Therapeutics Incorporated filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing indica
• Prelude Therapeutics Files 8-K — 8-K · Jun 12, 2024 Risk: low
  On June 12, 2024, Prelude Therapeutics Incorporated filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exh
• Prelude Therapeutics Files 8-K/A Amendment — 8-K/A · May 16, 2024 Risk: medium
  Prelude Therapeutics Incorporated filed an amendment (8-K/A) on May 16, 2024, to a report originally dated April 8, 2024. This amendment pertains to the departu
• Prelude Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
  Prelude Therapeutics Inc (PRLD) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Filed a 10-Q report for the period ending March 31, 2024. The filin
• Prelude Therapeutics Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 26, 2024 Risk:
  Prelude Therapeutics Inc (PRLD) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The 2024 Annual Meeting of Stockholders for Prelude Therapeuti
• Prelude Therapeutics Appoints New Chief Medical Officer — 8-K · Apr 10, 2024 Risk: medium
  On April 8, 2024, Prelude Therapeutics Incorporated announced the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer. Dr. Drachman previously serv
• Prelude Therapeutics Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 15, 2024 Risk: medium
  Prelude Therapeutics Inc (PRLD) filed a Annual Report (10-K) with the SEC on February 15, 2024. Prelude Therapeutics Inc. filed its 2023 Form 10-K on February 1
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Prelude Therapeutics: Dr. Krishna Vaddi Holds 10% Stake — SC 13G/A · Feb 12, 2024 Risk: low
  Dr. Krishna Vaddi, a key figure at Prelude Therapeutics Inc., filed an amended SC 13G/A on February 12, 2024, disclosing his beneficial ownership of 4,908,086 s
• Deerfield Mgmt Discloses 4.13M Shared Vote in Prelude Therapeutics — SC 13G/A · Feb 12, 2024 Risk: low
  Deerfield Management Company, L.P. and its affiliates, including Deerfield Mgmt, L.P. and Deerfield Partners, L.P., filed an amended SC 13G/A on February 12, 20
• FMR LLC Cuts Prelude Therapeutics Stake to 0.630% — SC 13G/A · Jan 10, 2024
  FMR LLC, a major investment firm, and its CEO, Abigail P. Johnson, have significantly reduced their stake in Prelude Therapeutics Inc. As of January 10, 2024, t

Related Companies

INCY

Frequently Asked Questions